Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 243

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 243
---
 31, 2023 there were no material adjustments to our prior period estimates of accrued expenses for clinical trials. 124

Results of Operations Comparison of the Years ended December 31, 2024 and 2023 The following table summarizes our consolidated results of operations for the years ended December 31, 2024 and 2023, and the change in the applicable line item in terms of dollars and percentage: Years Ended December 31, Change 2024 2023 $ % Revenue License fee revenue $ — $ 1,000,000 $ (1,000,000) (100) % Milestone revenue — 1,800,000 (1,800,000) (100) % Royalty revenue 9,784 7,885 1,899 24 % Total revenue 9,784 2,807,885 (2,798,101) (100) % Operating expenses General and administrative expenses $ 9,156,061 $ 12,109,691 $ (2,953,630) (24) % Research and development expenses 14,205,208 21,538,074 (7,332,866) (34) % License fee expenses 100,000 100,000 — — % Total operating expenses 23,461,269 33,747,765 (10,286,496) (30) % Loss from operations (23,451,485) (30,939,880) 7,488,395 24 % Other income (expense) Sale of royalty and milestone rights, net 20,379,376 — 20,379,376 100 % Other income (expense), net (981,490) 778,489 (1,759,979) (226) % Net loss $ (4,053,599) $ (30,161,391) $ 26,107,792 (87) % Revenues Revenues for the years ended December 31, 2024 and 2023 related to our license agreement with Organon to commercialize XACIATO. For 2023, we recognized $1.0 million in license fee revenue upon execution of the amendment to the license agreement in July 2023, $1.8 million in milestone revenue in connection with the first commercial sale of XACIATO, and approximately $7,900 in royalties from net sales of XACIATO in the fourth quarter. General and administrative expenses The decrease of approximately